Xujie Zhao
Associate Professor
Office: Advanced Institute for Life and Health Room 213
Lab: Advanced Institute for Life and Health Second Floor
Email: chaoren640@163.com
Educations:
2004.9—2008.7 Henan Univesity，B.S., Biotechnology;
2008. 9—2012. 5 Shanghai Jiaotong University, M.S., Biochemistry and Molecular Biology;
2015. 9—2021. 5 The University of Tennessee Health Science Center/ St. Jude Children’s Research Hospital, Ph.D., Biomedical Sciences;
Positions:
2012. 7—2014. 8, Product Specialist, Division of Instruments Gene, Company Ltd;
2014. 9—2015. 8, Research Technologist, Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, USA;
2021. 6—2022. 11, Postdoc Research Associate, Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, USA;
2023. 9—present, Associate Professor, Advanced Institute of Life and Health, Southeast University, Nanjing, China.
Research Summary：We employ multi-omics approaches to identify tumor driver genes and their interacting proteins, uncovering their functions and regulatory mechanisms in both normal and cancer cells. Our research spans from elucidating the fundamental molecular mechanisms governing tumor driver gene regulation to discovering therapeutic targets for addressing drug resistance, metastasis, and relapse in cancers.
Publications:
1. Xujie Zhao*, Ping Wang*, Jonathan D. Diedrich, Jingliao Zhang, Wentao Yang, Kelly Barnett, Beisi Xu, Zhenhua Li, Allen Eng Juh Yeoh, Marina Konopleva, Chia-Lin Wei, Ching-Hon Pui, Daniel Savic, Jun J. Yang†. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. Nature Communications. 2022 Sep 14;13(1):5401. (PMID: 36104354; Top 50 selected papers)
2. Shaela Wright*, Xujie Zhao*, Wojciech Rosikiewicz, Shelby Mryncza, Judith Hyle, Wenjie Qi, Zhenling Liu, Siqi Yi, Yong Cheng, Beisi Xu & Chunliang Li. Systematic characterization of the HOXA9 downstream targets in MLL-r leukemia by noncoding CRISPR screens. Nature Communications 14, 7464 (2023). (PMID: 38016946)
3. Xujie Zhao*, Maoxiang Qian*, Charnise Goodings*, Wentao Yang, Yang Zhang, Wenjian Yang, Ping Wang, Beisi Xu, Cheng Tian, Ching-Hon Pui, Stephen P. Hunger, Elizabeth A. Raetz, Meenakshi Devidas, Mary V. Relling, Mignon L. Loh, Daniel Savic, Chunliang Li, Jun J. Yang†. Molecular mechanisms of ARID5B-mediated genetic susceptibility to acute lymphoblastic leukemia. J Natl Cancer Inst. 2022 May 16;djac101. (PMID:35575404)
4. Heng Xu*, Xujie Zhao*, Deepa Bhojwani, E Shuyu, Charnise Goodings, Hui Zhang, Nita L Seibel, Wentao Yang, William L Carroll, William E Evans, Jun J Yang. ARID5B influences anti-metabolite drug sensitivity and prognosis of acute lymphoblastic leukemia. Clinical Cancer Research 26(1):256-264, 2020. (PMID: 31573954)
5. Charnise Goodings*, Xujie Zhao*, Shannon McKinney-Freeman, Hui Zhang, Jun J. Yang†. ARID5B influences B cell development and function in mouse. Haematologica. 2022 Aug 4. (PMID: 35924577)
6. Siyang Wang*, Yabin Liu*, Xujie Zhao*, Xiaoling Wang, Jiacheng Lou, Peng Jin, Yi Zhang, Jinyi Yu, Kankan Wang. RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core‐binding factor‐acute myeloid leukaemia. BJHaem. 2024 27 May. (PMID: 38802066)
